A multifaceted treatment approach including education, nonpharmacologic therapies, and medications was described for 12 patients with disabling orthostatic and supine hypertension.
Case Report (n=12)
No
A stepwise treatment approach combining nonpharmacologic maneuvers and targeted pharmacotherapy is proposed for managing disabling orthostatic hypotension and supine hypertension.
Orthostatic hypotension (OH) is a relatively common heterogeneous and multifactorial disorder often caused by autonomic dysfunction. This condition has a deleterious impact on quality of life and contributes to higher mortality rates. Supine hypertension is very common in patients with autonomic failure, limits the use of pressor agents, and can result in end-organ damage. Current recommendations on the optimal management of these patients are based on expert opinion and poor-quality small cross-sectional studies including patients with primary autonomic failure and severe orthostatic hypotension. The authors present their treatment approach in 12 patients with disabling orthostatic hypotension and supine hypertension not related to primary autonomic failure, presenting to a referral center over a 4-year period. The first step is to educate the patient about the pathophysiology and course of their disorder. Nonpharmacologic therapies and maneuvers are usually effective in relieving symptoms and preventing syncope. If needed, pharmacologic options such as fludrocortisones and midodrine are also available in patients with severe symptoms. Supine hypertension represents a challenge in the treatment of this condition. Therefore, elevation of the bed of the head and dosing of short-acting antihypertensive agents at bedtime is often indicated.
Briasoulis et al. (Sat,) conducted a case report in Disabling orthostatic hypotension and supine hypertension (n=12). Multifaceted treatment approach (education, nonpharmacologic therapies, and pharmacotherapy) was evaluated. A multifaceted treatment approach including education, nonpharmacologic therapies, and medications was described for 12 patients with disabling orthostatic and supine hypertension.